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Abstract 
The effect of  complement fragments on coronary  blood flow in vivo and the contraction of  coronary  
arteries in vitro was determined. In pentobarbital anesthetized dogs, intraarterial bolus injection of  C3a 
and C5a, zymosan-activated serum and methylcholine in the coronary  vascular bed caused transient and 
dose-dependent increases in coronary  blood flow, Similar increases were obtained with 25 lag of  C3a 
(104__ 13 %, n = 5) and 0.1 lag of  methylcholine (102 _+ 4%, n = 3). Smaller increases in blood flow were 
elicited by 25 lag of  C5a (41 _ 18 %, n = 4) and 0.2 ml of  zymosan-activated serum (48 _ 5%, n--4).  None 
of  these responses were associated with significant changes in left ventricular contractile force measured 
with a strain gauge, arterial blood pressure, and heart rate. C3a dilated the coronary  vascular bed in 
conscious dogs with an activity equal to or greater than that observed in anesthetized dogs. Isolated 
canine coronary  arteries that were precontracted with serotonin relaxed in response to C3a, whether or 
not  the endothelium was intact. Overall these data suggest that physiologically high doses of  anaphylae- 
tic complement fragments vasodilate the canine coronary circulation. 
Introduction 
Activation of  the complement cascade has been 
observed in the rat [1], dog [2] and monkey [3] 
heart during myocardial  ischemia. It is not  certain 
whether this process is a causative factor or an 
epiphenomenon of  mycocardial  infarction, how- 
ever depletion of  complement prior to ischemia 
has been found to be cardioprotective [4]. The ana- 
phylactic complement fragments C3a and C5a 
possess potent  vasospastic and chemotactic activi- 
ties [5] which could contribute directly or indirectly 
to the impairment o f  cardiac function and coro- 
nary blood flow (CBF) that accompany reperfu- 
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sion o f  ischemic myocardium. The observation by 
several laboratories that the intracoronary injec- 
tion of  C5a into pigs reduces coronary blood flow 
and causes cardiac dysfunction [6-8]  suggests that 
the anaphylatoxins could contribute to the patho- 
physiology of  myocardial  ischemia. In the present 
study the effect o f  C3a, C5a and zymosan-acti- 
vated plasma (ZAS) on the coronary  vascular bed 
of  dogs in vivo and on epicardial canine coronary 
arteries in vitro was determined. 
Materials and methods 
Vascular responses to anaphylatoxins in vivo 
In the anesthetized preparation five male mongrel 
dogs (17 to 22 kg) were given sodium pentobarbi- 
tal (30 mg/kg, i.v.) and ventilated with room air 
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using a model 607 respirator pump (Harvard Ap- 
paratus, South Natick, MA). A carotid artery was 
catheterized to monitor arterial blood pressure 
(ABP) by use of a P23Db transducer (Gould Inc., 
Oxnard, CA). A left thoracotomy was performed 
at the 5th intercostal space and the left circumflex 
coronary artery was isolated proximal to the ob- 
tuse diagonal branch. A cannula (27-gauge, U- 
shaped hypodermic needle attached to 0.03 inch 
bore tygon tubing) was inserted into the LCCA for 
intracoronary injections, and distal to this an 
EP407 and EP408 electromagnetic flow probe 
(Carolina Medical Instruments, King, NC) was 
attached to the vessel. A Walton-Brodie strain 
gauge arch (Warren Research Products, Charleston, 
SC) was sutured to the left ventricle in the left 
circumflex coronary artery perfusion bed to mea- 
sure isometric contractile force as described pre- 
viously [9]. CBF, ABP, heart rate and developed 
contractile force were recorded continuously on a 
model 7 polygraph (Grass Medical Instruments, 
Charleston, SC). 
In the conscious preparation the left circumflex 
coronary artery of six male dogs was instrumented 
with the intracoronary cannula and flow probe as 
described for the anesthetized preparation. 
Surgery was performed under aseptic conditions 
and a week was allowed for recovery. Experimen- 
tal studies were performed in infection-free, con- 
scious and unsedated dogs that were resting qui- 
etly in a nonrestrictive sling. CBF, ABP and heart 
rate were recorded as described previously. 
Intracoronary injections (0.2 ml) of  C3a (anes- 
thetized and conscious dogs) and C5a (anes- 
thetized clogs only) were given over 15 sec in order 
of increasing dose (3 to 25 ~g) and spaced approx- 
imately 10 min apart for recovery of baseline CBE 
In most experiments methylcholine chloride 
(MeCh, 0.1 ~tg) and ZAS (0.2 ml) were adminis- 
tered in a similar manner. The order of C3a and 
C5a injections was randomized. In three of  the 
anesthetized dogs the 6 ~tg C3a dose was repeated 
after the 25 ~tg dose to determine if sensitivity to 
the anaphylatoxin had diminished. In two of the 
conscious dogs responses to 25 ~tg of C3a were 
repeated after 1 to 2 days to assess reproducibility. 
Vascular responses to complement in vitro 
Male mongrel dogs were anesthetized as described 
previously and the left anterior descending coro- 
nary artery was excised. The artery was placed in 
a physiological salt solution at 4 ~ which had the 
following composition (mmol/1): NaC1 130; KC1 
4.7; KH2PO 4 1.18; MgSO4.7H20 1.17; CaC1 z 
-H20 1.6; NaHCO 3 14.9; dextrose 5.5; CaNa 2 
EDTA 0.03. Arteries were then cut into helical 
strips (1.5 x 10 mm) and mounted vertically in a 
tissue bath containing physiological salt solution 
aerated with 95% 02-5% CO2 at 37~ to a 
pH 7.4. Arterial strips were attached to FT.03 
force transducers (Grass Medical Instruments) 
and placed under 1.0 g of  tension. After 2 h of 
equilibration responses to C3a (0.1 to 1.0 ~tg/ml) 
were determined either directly or after eliciting 
contraction with serotonin (1 pmol/1). Additional 
experiments were performed on arteries that were 
rubbed prior to mounting to disrupt the endothe- 
lium, which was verified by loss of acetylcholine- 
induced relaxation. 
Materials and statistical analysis 
ZAS was prepared by incubating canine serum 
with 1 mg/ml of zymosan particles (Sigma Chemi- 
cal Co., St. Louis, MO) at 37~ for 30 min and 
then separating the serum by centrifugation. Hu- 
man C5a and C3a were isolated by an enzyme- 
linked immunoabsorbent assay from serum which 
was activated with zymosan in the presence of a 
carboxypeptidase inhibitor to prevent formation 
of des arg metabolites [10], and they were sus- 
pended in saline. Complement fragments and ZAS 
were stored at -70  ~ and thawed immediately be- 
fore use. 
All data in the text and figures are presented as 
mean + SEM. Statistical analyses were performed 
by computer-assisted t-test for two-way compari- 
sons, or analysis of variance with repeated mea- 
sures and contrast for multiple comparisons (Sys- 
tat, Evanston, IL). A p < 0.05 was considered sig- 
nificant. 
Results 
Vascular responses to complement in vivo 
Anesthetized dogs reacted to intracoronary injec- 
tion of C3a and C5a with increases in CBF. No 
reductions in CBF were detected in any animal 
tested. The dose-dependent and reversible nature 
of these vasodilator responses is demonstrated by 
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the physiological recordings obtained from one 
dog during administration of C3a (Fig. 1). Quali- 
tatively similar results were obtained with C5a, 
ZAS and MeCh in this and other experiments, 
although there was considerable variability among 
animals in the magnitude of the CBF increases. 
Overall, baseline CBF (27_+2ml/min) was in- 
creased 29_+5ml/min by C3a (25lag; n=5) ,  
11 + 6 ml/min by C5a (25 lag; n = 4), 15 ___ 3 ml/min 
by ZAS (0.2ml; n=4) ,  and 29_+3 ml/min by 
MeCh (0.1 ~g; n=3)  (Fig. 2). C3a was more active 
than C5a in both this analysis, and also when coro- 
nary vascular responses were quantitated as vol- 
ume (ml) increases determined as area under the 
CBF trace by planimetry (Fig. 2). CBF was not 
affected by intracoronary injections of C3a and 
C5a which had been heat-inactivated (56~ for 
1 h), or canine serum which was not activated by 
zymosan particles (not shown). Baseline mean 
ABP (123_+4mmHg) heart rate (177+4 beats/ 
min) and developed left ventricular contractile 
force (92 4- 5 g) were not significantly altered dur- 
ing peak increases in CBF induced by 25 lag of C3a 
(124-+5 mmHg, 179+4 beats/min and 100+6 g, 
respectively; n=  5). Injections of C5a, ZAS, and 
lower doses of C3a likewise had no significant ef- 
fect on ABP or left ventricular contractility (not 
shown). 
The effect of C3a on CBF in conscious dogs was 
studied in separate experiments. Coronary vascu- 
lar responses to C3a in the conscious dog were 
characterized by dose-dependent increases in CBF 
that were qualitatively similar to those observed in 
anesthetized dogs (Fig. 3). The increase in CBF 
(50-+ 4 ml/min, n = 5) above baseline levels 
(21__+1 ml/min) elicited by 25 lag of C3a was 
greater (p < 0.01) than the corresponding response 
observed in anesthetized dogs. However, the total 
volume of this flow response did not differ signifi- 
cantly between anesthetized and conscious prepa- 
rations (22 + 6 and 25_+ 2 ml, respectively). When 
dogs were exposed to a single 25 lag injection of 
C3a after 1 or 2 days the magnitude of the flow 
increase was within 20% of the initial response. 
Vascular responses to complement in vitro 
Canine coronary arteries that were contracted with 
serotonin relaxed upon addition of 0.5 lag/ml of 
C3a (Fig. 4), whether or not the endothelium was 
intact. Higher C3a concentrations (1 lag/ml) did 
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Figure l MeCh C3a 
Physiological responses of a single pentobarbital-anesthetized 
dog were determined during sequential intraarterial injections of 
methylcholine (MeCh) and C3a into the coronary circulation. In 
this and in two other experiments the response to 6 pg of the 
anaphylatoxin was similar before and after the 25 lag dose. 
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Intraarterial (i.a.) injections of C3a, C5a, zymosan-activated se- 
rum (ZAS) and methylcholine (MeCh) were given to pentobarbi- 
tal-anesthetized dogs. Coronary vascular responses were mea- 
sured as mean above control baseline flow (C) and as total 
increase in blood volume. C3a responses were greater than C5a 
responses (p<0.05 at 12.5 and 25 lag). 
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Single intraarterial injections (i.a.) of C3a and methylcholine 
(MeCh) were given to conscious dogs. Coronary vascular re- 
sponses were measured as increase above control baseline flow 
(C) and as total increase in blood volume, which was measured 
as area under the CBF trace by planimetry. 
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Vascular responses to C3a were determined in vitro in two canine 
coronary artery strips that were first contracted with serotonin. 
The endothelium was removed from one the arteries by rubbing. 
Data are representative of 3 similar experiments. 
not cause greater relaxation and similar responses 
were observed in arteries exposed to C3a (0.5 lag/ 
ml) without serotonin-induced contraction (not 
shown). The maximum reduction in contractile 
force induced by C3a was greater in pharmacolog- 
ically contracted ( -  150 rag) compared to unstimu- 
lated arteries (-48 mg). 
Discussion 
In anesthetized dogs intracoronary injections of 
C3a, C5a and ZAS transiently increased but never 
decreased CBF, and this occurred without concur- 
rent changes in ABP, heart rate or regional my- 
ocardial contractility. Intravenous administration 
of C5a has been found by others to reduce ABP in 
dogs [11], and therefore the absence of a ABP re- 
sponse in our preparation demonstrates that ana- 
phylatoxin exposure was effectively limited to the 
coronary circulation. While it is possible that the 
use of  human C3a and C5a could have influenced 
the vascular response, the fact that canine ZAS 
produced similar although smaller responses ar- 
gues against this. Of the two anaphylatoxins C5a 
had less vascular activity since reductions in coro- 
nary vascular resistance were more than two-fold 
greater with C3a. Although we did not address the 
issue of tachyphylaxis to repeated high injections 
of anaphylatoxins in these experiments, the re- 
sponse to 6 lag of C3a was not diminished after 
exposure to the 12.5 and 25 tx doses (Fig. 1). 
Vascular responses to C3a, C5a and ZAS were 
qualitatively similar and therefore only C3a was 
studied in conscious dogs. These experiments were 
performed to eliminate interfering factors related 
to anesthetic or acute surgical trauma. Responses 
in conscious and anesthetized dogs proved to be 
qualitatively similar, although maximum CBF in- 
creases (ml/min) to C3a were greater in conscious 
animals. In the conscious canine 3 lag of C3a elic- 
ited a transient 11_ 3 ml/min (n = 5) increase in 
CBF, which assuming a 15 sec injection into the 
respective baseline CBF (~20ml /min)  corre- 
sponds to a transient blood level of ~0.6 lag/ml. 
This estimate compares well with the reported C3a 
plasma concentration (0.6+0.09 lag/ml) detected 
in patients undergoing thrombolytic therapy for 
acute myocardial infarction [12]. When the reactiv- 
ity of  the canine coronary vasculature to anaphyla- 
toxin was compared to a cholinergic stimulus, the 
C3a dose producing an equivalent response was 
50-fold greater than the MeCh dose. However the 
molecular weight (g/mole) of C3a (3 x 103) greatly 
exceeds that of MeCh (196), and if vasodilation 
resulted from receptor occupation this difference 
should be corrected for in any comparison. We did 
not study > 25 lag injections of C3a and C5a due to 
the limited supply and concerns regarding the 
physiological relevance of higher doses. Thus it is 
not known if the vascular responses were maximal. 
C3a produced only vasorelaxation of coronary ar- 
tery strips in vitro. The epicardial artery response 
was thus similar to the small vessel response ob- 
served in vivo, and it did not appear to involve 
EDRF since it persisted in the absence of endothe- 
lium. 
Other investigators have observed reductions in 
both CBF and myocardial contractility in response 
to the intracoronary injection of C5a into anes- 
thetized pigs [6-8]. The C5a dose (0.5 lag) that was 
active in the pig [7, 8] was 25-fold lower than the 
threshold dose of C5a which increased CBF in our 
anesthetized canine preparation. One hypothesis 
which addresses the disparity between these results 
and ours raises the issue of species differences in 
the production or reactivity to secondary media- 
tors, especially TxA2. There is good evidence that 
autocoids and prostaglandins are involved in the 
action of activated complement on smooth muscle 
[5, 13, 14]. TxA2-receptors participate in CBF re- 
ductions produced by C5a in the pig as evidenced 
by the near complete antagonism obtained with 
TxAz-receptor antagonists [7, 8], although peptide 
leukotrienes may also contribute to the response 
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[7]. The coronary vasculature of  the pig is very 
reactive to Tx-mimetics, such as U-46,619, and in- 
creased production of TxA 2 (measured as TxB2) 
has been found to accompany C5a-induced vaso- 
constriction [7, 8]. In contrast, the coronary vascu- 
lature of the adult dog has been reported to be 
relatively unreactive to endogenous and pharma- 
cologic activators of TxA2-receptors [15, 16]. 
Other canine vascular beds including the pul- 
monary, mesenteric and renal circulations respond 
more consistently to local injection of U-46,619 
with dose-dependent reductions in vascular resis- 
tance [16, 17]. 
Our results emphasize the importance of species 
variability in the vascular reactivity to anaphyla- 
toxins and demonstrate that complement frag- 
ments are relatively weak vasodilators in the ca- 
nine coronary circulation. Since other pharmaco- 
logic interventions were not examined, we do not 
know if the action of anaphylatoxins on the canine 
coronary circulation are direct or indirect. We also 
do not know if acute exposure of  the canine vascu- 
lature to activated complement causes neutrophil 
sequestration [6] or neutrophil-dependent plasma 
exudation [18] as reported with other species. In 
comparison to our canine studies, activation of the 
complement cascade in human pathophysiology 
may be both more sustained and accompanied by 
reperfusion of ischemic tissue. These additional 
factors could in turn lead to a qualitatively differ- 
ent myocardial vascular response. 
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